Published in Arterioscler Thromb Vasc Biol on July 06, 2006
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Optical and multimodality molecular imaging: insights into atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.84
Multimodality cardiovascular molecular imaging, Part II. Circ Cardiovasc Imaging (2009) 1.82
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest (2009) 1.78
Perspectives and opportunities for nanomedicine in the management of atherosclerosis. Nat Rev Drug Discov (2011) 1.78
Molecular imaging in atherosclerosis, thrombosis, and vascular inflammation. Arterioscler Thromb Vasc Biol (2009) 1.65
Paracrine induction of endothelium by tumor exosomes. Lab Invest (2009) 1.63
Magnetic nanoparticles for MR imaging: agents, techniques and cardiovascular applications. Basic Res Cardiol (2008) 1.60
Nanotechnology in medical imaging: probe design and applications. Arterioscler Thromb Vasc Biol (2008) 1.55
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett (2008) 1.47
Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J (2010) 1.42
Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J (2008) 1.41
Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann Biomed Eng (2009) 1.39
Inflammation imaging in atherosclerosis. Arterioscler Thromb Vasc Biol (2009) 1.38
Responsive theranostic systems: integration of diagnostic imaging agents and responsive controlled release drug delivery carriers. Acc Chem Res (2011) 1.31
Molecular imaging of atherosclerosis for improving diagnostic and therapeutic development. Circ Res (2012) 1.29
Enabling individualized therapy through nanotechnology. Pharmacol Res (2010) 1.28
Cardiovascular molecular imaging: focus on clinical translation. Circulation (2011) 1.24
Imaging and nanomedicine in inflammatory atherosclerosis. Sci Transl Med (2014) 1.23
Emerging applications of nanomedicine for the diagnosis and treatment of cardiovascular diseases. Trends Pharmacol Sci (2010) 1.22
Nanoparticle pharmacokinetic profiling in vivo using magnetic resonance imaging. Magn Reson Med (2008) 1.19
Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev (2012) 1.18
Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano (2009) 1.18
Theragnostics for tumor and plaque angiogenesis with perfluorocarbon nanoemulsions. Angiogenesis (2010) 1.17
High sensitivity: high-resolution SPECT-CT/MR molecular imaging of angiogenesis in the Vx2 model. Invest Radiol (2009) 1.15
Molecular imaging of atherosclerotic plaques targeted to oxidized LDL receptor LOX-1 by SPECT/CT and magnetic resonance. Circ Cardiovasc Imaging (2010) 1.14
Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice. FASEB J (2009) 1.13
Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials (2008) 1.12
Simultaneous dual-nuclei imaging for motion corrected detection and quantification of 19F imaging agents. Magn Reson Med (2011) 1.10
Imaging atherosclerosis and vulnerable plaque. J Nucl Med (2010) 1.10
Lymphocytes and the adventitial immune response in atherosclerosis. Circ Res (2012) 1.09
Targeted probes for cardiovascular MRI. Future Med Chem (2010) 1.02
Mechanisms of nucleotide trafficking during siRNA delivery to endothelial cells using perfluorocarbon nanoemulsions. Biomaterials (2010) 1.02
Lipid membrane editing with peptide cargo linkers in cells and synthetic nanostructures. FASEB J (2010) 1.00
Quantitative magnetic resonance fluorine imaging: today and tomorrow. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 1.00
Molecular imaging with targeted perfluorocarbon nanoparticles: quantification of the concentration dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med Biol (2007) 1.00
Nanomedicine strategies for molecular targets with MRI and optical imaging. Future Med Chem (2010) 0.99
Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles. Radiology (2013) 0.97
Targeting of alpha(nu)beta(3)-integrins expressed on tumor tissue and neovasculature using fluorescent small molecules and nanoparticles. Nanomedicine (Lond) (2010) 0.95
Inflammation and neovascularization intertwined in atherosclerosis: imaging of structural and molecular imaging targets. Circulation (2014) 0.95
Angiogenesis is required for stress fracture healing in rats. Bone (2012) 0.95
Optical techniques for the molecular imaging of angiogenesis. Eur J Nucl Med Mol Imaging (2010) 0.94
Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles. Biomaterials (2012) 0.93
Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm. ACS Nano (2014) 0.92
Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug. Nanomedicine (Lond) (2012) 0.91
MR angiogenesis imaging with Robo4- vs. alphaVbeta3-targeted nanoparticles in a B16/F10 mouse melanoma model. FASEB J (2010) 0.91
Multifunctional imaging nanoprobes. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.91
Polymer-based therapeutics: nanoassemblies and nanoparticles for management of atherosclerosis. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2011) 0.91
New mechanisms for non-porative ultrasound stimulation of cargo delivery to cell cytosol with targeted perfluorocarbon nanoparticles. Nanotechnology (2008) 0.90
Collagen-specific peptide conjugated HDL nanoparticles as MRI contrast agent to evaluate compositional changes in atherosclerotic plaque regression. JACC Cardiovasc Imaging (2013) 0.90
Biomarkers of atherosclerosis and the potential of MRI for the diagnosis of vulnerable plaque. MAGMA (2007) 0.90
Molecular imaging of angiogenic therapy in peripheral vascular disease with alphanubeta3-integrin-targeted nanoparticles. Magn Reson Med (2010) 0.90
A fibrin-specific thrombolytic nanomedicine approach to acute ischemic stroke. Nanomedicine (Lond) (2011) 0.90
MR-optical imaging of cardiovascular molecular targets. Basic Res Cardiol (2008) 0.89
Therapeutic strategies to deplete macrophages in atherosclerotic plaques. Br J Clin Pharmacol (2012) 0.88
Macrophage targeted theranostics as personalized nanomedicine strategies for inflammatory diseases. Theranostics (2015) 0.87
Molecular imaging in cardiovascular magnetic resonance imaging: current perspective and future potential. Top Magn Reson Imaging (2008) 0.87
Tyrosine polyethylene glycol (PEG)-micelle magnetic resonance contrast agent for the detection of lipid rich areas in atherosclerotic plaque. Magn Reson Med (2009) 0.86
Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles. Theranostics (2014) 0.86
Nanoparticles as magnetic resonance imaging contrast agents for vascular and cardiac diseases. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.86
Rationale for a nanomedicine approach to thrombolytic therapy. Stroke (2010) 0.84
Quantitative cardiovascular magnetic resonance for molecular imaging. J Cardiovasc Magn Reson (2010) 0.84
Rapamycin nanoparticles target defective autophagy in muscular dystrophy to enhance both strength and cardiac function. FASEB J (2014) 0.84
Nanomedicine captures cardiovascular disease. Arterioscler Thromb Vasc Biol (2008) 0.83
Characterization of perfluorooctylbromide-based nanoemulsion particles using atomistic molecular dynamics simulations. J Phys Chem B (2010) 0.83
MR molecular imaging of aortic angiogenesis. JACC Cardiovasc Imaging (2010) 0.82
Nanomedical Theranostics in Cardiovascular Disease. Curr Cardiovasc Imaging Rep (2011) 0.81
Vasa vasorum in atherosclerosis and clinical significance. Int J Mol Sci (2015) 0.81
Nanoparticles for Cardiovascular Imaging and Therapeutic Delivery, Part 1: Compositions and Features. J Nucl Med (2015) 0.80
CD44 targeting magnetic glyconanoparticles for atherosclerotic plaque imaging. Pharm Res (2013) 0.80
Insights into atherosclerosis using nanotechnology. Curr Atheroscler Rep (2010) 0.80
SPECT/CT Imaging of High-Risk Atherosclerotic Plaques using Integrin-Binding RGD Dimer Peptides. Sci Rep (2015) 0.80
Cell Labeling for 19F MRI: New and Improved Approach to Perfluorocarbon Nanoemulsion Design. Biosensors (Basel) (2013) 0.80
Imaging of apoptosis in the heart with nanoparticle technology. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2010) 0.80
Molecular imaging of atherosclerosis in translational medicine. Eur J Nucl Med Mol Imaging (2010) 0.80
Cardamonin Regulates miR-21 Expression and Suppresses Angiogenesis Induced by Vascular Endothelial Growth Factor. Biomed Res Int (2015) 0.79
Molecular imaging of plaques in coronary arteries with PET and SPECT. J Geriatr Cardiol (2014) 0.79
Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis. Curr Cardiovasc Imaging Rep (2012) 0.79
Perfluorocarbon nanoparticles: evolution of a multimodality and multifunctional imaging agent. Scientifica (Cairo) (2014) 0.79
Multifunctional agents for concurrent imaging and therapy in cardiovascular disease. Adv Drug Deliv Rev (2010) 0.79
A brief account of nanoparticle contrast agents for photoacoustic imaging. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2013) 0.78
Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma. Int J Nanomedicine (2014) 0.78
Contact-mediated intracellular delivery of hydrophobic drugs from polymeric nanoparticles. Cancer Nanotechnol (2014) 0.78
In vivo molecular imaging of vascular stress. Cell Stress Chaperones (2008) 0.78
alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment. Theranostics (2015) 0.78
Advances in nanotechnology for the management of coronary artery disease. Trends Cardiovasc Med (2012) 0.78
Nanomedicines for Endothelial Disorders. Nano Today (2015) 0.77
Design of nanovectors for therapy and imaging of cardiovascular diseases. Methodist Debakey Cardiovasc J (2012) 0.77
MR molecular imaging of angiogenesis using targeted perfluorocarbon nanoparticles. Medicamundi (2010) 0.77
Delivery of Polymeric Nanoparticles to Target Vascular Diseases. J Biomol Res Ther (2014) 0.77
Perfluorocarbon nanoparticles for physiological and molecular imaging and therapy. Adv Chronic Kidney Dis (2013) 0.77
Molecular MRI of Atherosclerotic Plaque With Targeted Contrast Agents. Curr Cardiovasc Imaging Rep (2009) 0.77
Molecular magnetic resonance imaging of atherosclerotic vessel wall disease. Eur Radiol (2015) 0.76
Engineering nanomaterials to address cell-mediated inflammation in atherosclerosis. Regen Eng Transl Med (2016) 0.76
Nanoimaging in cardiovascular diseases: Current state of the art. Indian J Med Res (2015) 0.76
Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery. Wiley Interdiscip Rev Nanomed Nanobiotechnol (2015) 0.76
Molecular imaging of atherosclerosis with nanoparticle-based fluorinated MRI contrast agents. Nanomedicine (Lond) (2015) 0.76
Advances in molecular imaging of atherosclerosis and myocardial infarction: shedding new light on in vivo cardiovascular biology. Am J Physiol Heart Circ Physiol (2012) 0.76
Atherosclerotic neovasculature MR imaging with mixed manganese-gadolinium nanocolloids in hyperlipidemic rabbits. Nanomedicine (2015) 0.76
Molecular MRI of the Cardiovascular System in the Post-NSF Era. Curr Cardiovasc Imaging Rep (2012) 0.75
Exosomes released by melanoma cells prepare sentinel lymph nodes for tumor metastasis. Cancer Res (2011) 3.73
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Molecular imaging of angiogenesis in nascent Vx-2 rabbit tumors using a novel alpha(nu)beta3-targeted nanoparticle and 1.5 tesla magnetic resonance imaging. Cancer Res (2003) 2.70
19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J (2007) 2.63
The magnitude of radiation force on ultrasound contrast agents. J Acoust Soc Am (2002) 2.38
Remodeling of cardiac fiber structure after infarction in rats quantified with diffusion tensor MRI. Am J Physiol Heart Circ Physiol (2003) 2.30
Molecular MR imaging of melanoma angiogenesis with alphanubeta3-targeted paramagnetic nanoparticles. Magn Reson Med (2005) 2.30
Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. JACC Cardiovasc Imaging (2008) 2.14
Noninvasive imaging of myocardial angiogenesis following experimental myocardial infarction. J Clin Invest (2004) 2.06
Deformation of biological cells in the acoustic field of an oscillating bubble. Phys Rev E Stat Nonlin Soft Matter Phys (2009) 2.02
Regional ventricular wall thickening reflects changes in cardiac fiber and sheet structure during contraction: quantification with diffusion tensor MRI. Am J Physiol Heart Circ Physiol (2005) 1.91
Nanotechnological applications in medicine. Curr Opin Biotechnol (2007) 1.90
Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med (2004) 1.83
Molecularly targeted nanocarriers deliver the cytolytic peptide melittin specifically to tumor cells in mice, reducing tumor growth. J Clin Invest (2009) 1.78
Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation (2002) 1.77
Effect of nanoparticle surface charge at the plasma membrane and beyond. Nano Lett (2010) 1.77
Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve stenosis: comparison with echocardiography. Circulation (2003) 1.73
Laminin receptor specific therapeutic gold nanoparticles (198AuNP-EGCg) show efficacy in treating prostate cancer. Proc Natl Acad Sci U S A (2012) 1.72
Quantitative "magnetic resonance immunohistochemistry" with ligand-targeted (19)F nanoparticles. Magn Reson Med (2004) 1.68
Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J (2008) 1.67
High-resolution MR imaging of the human eye 2005. Acad Radiol (2006) 1.65
Paracrine induction of endothelium by tumor exosomes. Lab Invest (2009) 1.63
A morphometric analysis of auditory brain regions in congenitally deaf adults. Proc Natl Acad Sci U S A (2003) 1.60
Computed tomography in color: NanoK-enhanced spectral CT molecular imaging. Angew Chem Int Ed Engl (2010) 1.57
Imaging of Vx-2 rabbit tumors with alpha(nu)beta3-integrin-targeted 111In nanoparticles. Int J Cancer (2007) 1.57
Detection of injury-induced vascular remodeling by targeting activated alphavbeta3 integrin in vivo. Circulation (2004) 1.57
In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med (2008) 1.56
Modulating pharmacokinetics, tumor uptake and biodistribution by engineered nanoparticles. PLoS One (2011) 1.53
Noninvasive photoacoustic and fluorescence sentinel lymph node identification using dye-loaded perfluorocarbon nanoparticles. ACS Nano (2010) 1.53
RNA interference knockdown of DNA methyl-transferase 3 affects gene alternative splicing in the honey bee. Proc Natl Acad Sci U S A (2013) 1.49
Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano Lett (2008) 1.47
Synthesis of NanoQ, a copper-based contrast agent for high-resolution magnetic resonance imaging characterization of human thrombus. J Am Chem Soc (2011) 1.47
Scintigraphic imaging of infectious foci with an 111In-LTB4 antagonist is based on in vivo labeling of granulocytes. J Nucl Med (2005) 1.47
Molecular photoacoustic tomography with colloidal nanobeacons. Angew Chem Int Ed Engl (2009) 1.47
Molecular imaging and therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging (2007) 1.46
Targeted contrast agents for magnetic resonance imaging and ultrasound. Curr Opin Biotechnol (2005) 1.43
Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol (2005) 1.42
Molecular photoacoustic imaging of angiogenesis with integrin-targeted gold nanobeacons. FASEB J (2010) 1.42